Churchill Management’s AstraZeneca AZN Stock Holding History

Churchill Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,373	Closed	-$568K	–	115
2019 Q3	$568K	Buy	+6,373	New	+$553K	0.01%	105

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Churchill Management's AZN Position: Q4 2019 in Review

Churchill Management sold out of AstraZeneca (AZN) in Q4 2019, closing a stake of 6,373 shares — an estimated $568K sold.

Churchill Management first reported a position in AZN in Q3 2019 and held it in 1 quarter. The position peaked at $568K in Q3 2019. 633 funds tracked by Wall St. Rank hold AZN as of Q4 2019.

Churchill Management reported no remaining AstraZeneca position as of Q4 2019 after selling out during the quarter.
Churchill Management sold 6,373 AstraZeneca shares in Q4 2019, an estimated $568K.
Churchill Management first reported a position in AstraZeneca in Q3 2019 and held it in 1 quarter.
Churchill Management's AstraZeneca position peaked at $568K in Q3 2019.
633 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2019.

Based on Churchill Management's 13F filing for Q4 2019, filed 22 Jan 2020.